# Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

> **NCT00005635** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.**

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00005635
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2001-11
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005635, "Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00005635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*